Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Delia Johnson

Showing results (41-50 of 88) with videos related to

Pageof 9
Sort By:
The American Journal of Medicine|January 9, 2003
Cholesterol-lowering medication, cholesterol level, and reproductive hormones in women: the Women's Ischemia Syndrome Evaluation (WISE)C Noel Bairey Merz, Marian B Olson, B Delia Johnson, et al.
Journal of Translational Medicine|March 12, 2008
Adrenergic gene polymorphisms and cardiovascular risk in the NHLBI-sponsored Women's Ischemia Syndrome EvaluationMichael A Pacanowski, Issam Zineh, Haihong Li, et al.
Psychosomatic Medicine|October 17, 2009
Comorbid depression and anxiety symptoms as predictors of cardiovascular events: results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) studyThomas Rutledge, Sarah E Linke, David S Krantz, et al.
Journal of Women'S Health (2002)|May 25, 2007
Phytoestrogens and coronary microvascular function in women with suspected myocardial ischemia: a report from the Women's Ischemia Syndrome Evaluation (WISE) StudyCarl J Pepine, Gregory O von Mering, Richard A Kerensky, et al.
The Journal of Clinical Endocrinology and Metabolism|August 27, 2010
DHEA-S levels and cardiovascular disease mortality in postmenopausal women: results from the National Institutes of Health--National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women's Ischemia Syndrome Evaluation (WISE)Chrisandra Shufelt, Philip Bretsky, Cristina M Almeida, et al.
Menopause (New York, N.Y.)|May 3, 2011
Timing of hormone therapy, type of menopause, and coronary disease in women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome EvaluationChrisandra L Shufelt, B Delia Johnson, Sarah L Berga, et al.
American Heart Journal|October 11, 2011
In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: A double-blind randomized study from the National Heart, Lung and Blood Institute Women's Ischemia Syndrome Evaluation (WISE)Daniel F Pauly, B Delia Johnson, R David Anderson, et al.
JAMA|September 9, 2004
Relationship of physical fitness vs body mass index with coronary artery disease and cardiovascular events in womenTimothy R Wessel, Christopher B Arant, Marian B Olson, et al.
Psychosomatic Medicine|December 26, 2007
Depression, the metabolic syndrome and cardiovascular riskViola Vaccarino, Candace McClure, B Delia Johnson, et al.
Journal of the American College of Cardiology|February 16, 2019
Impact of Abnormal Coronary Reactivity on Long-Term Clinical Outcomes in WomenAhmed AlBadri, C Noel Bairey Merz, B Delia Johnson, et al.
Pageof 9

Showing results (41-50 of 88) with videos related to

Sort By:
Pageof 9
The American Journal of Medicine|January 9, 2003
Cholesterol-lowering medication, cholesterol level, and reproductive hormones in women: the Women's Ischemia Syndrome Evaluation (WISE)C Noel Bairey Merz, Marian B Olson, B Delia Johnson, et al.
Journal of Translational Medicine|March 12, 2008
Adrenergic gene polymorphisms and cardiovascular risk in the NHLBI-sponsored Women's Ischemia Syndrome EvaluationMichael A Pacanowski, Issam Zineh, Haihong Li, et al.
Psychosomatic Medicine|October 17, 2009
Comorbid depression and anxiety symptoms as predictors of cardiovascular events: results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) studyThomas Rutledge, Sarah E Linke, David S Krantz, et al.
Journal of Women'S Health (2002)|May 25, 2007
Phytoestrogens and coronary microvascular function in women with suspected myocardial ischemia: a report from the Women's Ischemia Syndrome Evaluation (WISE) StudyCarl J Pepine, Gregory O von Mering, Richard A Kerensky, et al.
The Journal of Clinical Endocrinology and Metabolism|August 27, 2010
DHEA-S levels and cardiovascular disease mortality in postmenopausal women: results from the National Institutes of Health--National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women's Ischemia Syndrome Evaluation (WISE)Chrisandra Shufelt, Philip Bretsky, Cristina M Almeida, et al.
Menopause (New York, N.Y.)|May 3, 2011
Timing of hormone therapy, type of menopause, and coronary disease in women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome EvaluationChrisandra L Shufelt, B Delia Johnson, Sarah L Berga, et al.
American Heart Journal|October 11, 2011
In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: A double-blind randomized study from the National Heart, Lung and Blood Institute Women's Ischemia Syndrome Evaluation (WISE)Daniel F Pauly, B Delia Johnson, R David Anderson, et al.
JAMA|September 9, 2004
Relationship of physical fitness vs body mass index with coronary artery disease and cardiovascular events in womenTimothy R Wessel, Christopher B Arant, Marian B Olson, et al.
Psychosomatic Medicine|December 26, 2007
Depression, the metabolic syndrome and cardiovascular riskViola Vaccarino, Candace McClure, B Delia Johnson, et al.
Journal of the American College of Cardiology|February 16, 2019
Impact of Abnormal Coronary Reactivity on Long-Term Clinical Outcomes in WomenAhmed AlBadri, C Noel Bairey Merz, B Delia Johnson, et al.
Pageof 9